STOCK TITAN

CG Oncology (CGON) Financials

CGON NASDAQ
Trailing 12 months to September 30, 2026
Revenue $6.2M +183.6% YoY
Net Income -$237.5M n/m YoY
EPS (Diluted) -$2.76 n/m YoY
Free Cash Flow -$189.2M n/m YoY
Market Cap $7.3B as of Nov 19, 2026
Price / Sales n/m outside the range published as a multiple, on $6.2M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 7.4x on $991.0M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CGON SEC filings page.

CG Oncology, Inc. (CGON) reported $6.2M in revenue over the twelve months to Sep 30, 2026, up 183.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CGON FY2025

CG Oncology remains a development-stage business: funding expanded its balance sheet while research spending and cash consumption grew faster than revenue.

Cash conversion remains weak: the 2025 net loss reached $161M while operating cash flow was -$132M, with free cash flow nearly identical. Revenue grew 254.7% from FY2024 to FY2025, yet operating cash flow became more negative, showing that scale has not converted into self-funding operations.

Research remains the largest operating commitment: R&D reached $117M versus SG&A of $73.5M in FY2025. However, SG&A grew 118.2% against R&D growth of 42.1%, indicating support costs expanded faster than research during the year.

The balance sheet is equity-funded rather than debt-funded: liabilities were 4.9% of assets in FY2025, while the current ratio was 24.6x. Reported liquidity measured 67.3 months of the latest annual outflow, a balance-sheet comparison that does not change the company’s ongoing operating losses.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 61 / 100
Financial Health Score 61/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of CG Oncology, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
74

CG Oncology, Inc. held $742.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $132.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and CG Oncology, Inc. scores 74/100 among other emerging companies.

Dilution
6

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. CG Oncology, Inc. scores 6/100 on it among other emerging companies.

R&D Intensity
81

CG Oncology, Inc. spent $116.6M on research and development in fiscal year 2025, which was 59.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and CG Oncology, Inc. scores 81/100 among other emerging companies.

Revenue Progress
94

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. CG Oncology, Inc. scores 94/100 on it among other emerging companies.

Burn Trend
14

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. CG Oncology, Inc. scores 14/100 on it among other emerging companies.

Balance Sheet
99

CG Oncology, Inc.'s cash, cash equivalents and investments came to $742.2M at the end of fiscal year 2025, against $39.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and CG Oncology, Inc. scores 99/100 among other emerging companies.

Altman Z-Score Safe
112.21

CG Oncology, Inc. scores 112.21, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $7.3B against total liabilities of $39.0M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/8

CG Oncology, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

CG Oncology, Inc. reported a net loss of $161.0M while operations used $132.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.6M
YoY-3.7%
QoQ+38.6%

CG Oncology, Inc. generated $1.6M in revenue in Q3 2026. This represents a decrease of 3.7% from the same quarter a year earlier. Against the prior quarter it is up 38.6%.

EBITDA
-$62.1M
YoYn/m
QoQn/m

CG Oncology, Inc.'s EBITDA was -$62.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$56.9M
YoYn/m
QoQn/m

CG Oncology, Inc. reported a net loss of $56.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.64
YoYn/m
QoQn/m

CG Oncology, Inc. earned -$0.64 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$48.8M
YoYn/m
QoQn/m

CG Oncology, Inc. recorded an outflow of $48.8M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$28.2M
YoY-37.4%
QoQ+43.9%

CG Oncology, Inc. held $28.2M in cash against $3.0M in long-term debt as of Q3 2026, with $46.4M of liabilities due within a year.

Shares Outstanding
89M
YoY+10.7%
QoQ+0.8%

CG Oncology, Inc. had 89M shares outstanding in Q3 2026. This represents an increase of 10.7% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
-66.4%
YoY-71.7pp

CG Oncology, Inc.'s gross margin was -66.4% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 71.7 percentage points from the same quarter a year earlier.

Return on Equity
-5.7%
YoY+0.6pp
QoQ+1.9pp

CG Oncology, Inc.'s quarterly ROE was -5.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.9 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$39.2M
YoY+40.7%
QoQ-28.2%

CG Oncology, Inc. invested $39.2M in research and development in Q3 2026. This represents an increase of 40.7% from the same quarter a year earlier. Against the prior quarter it is down 28.2%.

Capital Expenditures
$1.1M
YoY+1049.5%
QoQ+138.2%

CG Oncology, Inc. invested $1.1M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 1049.5% from the same quarter a year earlier. Against the prior quarter it is up 138.2%.

Share Buybacks

Not reported for Q3 2026.

CGON Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CGON quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$1.6M-3.7%$1.2Mn/m$1.1M+1982.7%$2.3M+409.2%$1.7M+3774.4%$0-100.0%$52K-90.2%$456K+45500.0%
Cost of Revenue$2.7M+69.2%N/AN/AN/A$1.6MN/AN/AN/A
Gross Profit-$1.1M-1296.6%N/AN/AN/A$89KN/AN/AN/A
R&D Expenses$39.2M+40.7%$54.7M+74.5%$43.7M+59.2%$30.0M+11.8%$27.9M+42.1%$31.3M+69.6%$27.5M+59.6%$26.8M+64.0%
SG&A Expenses$23.0M-1.6%$29.0M+66.4%$20.8M+40.5%$18.0M+53.7%$23.3M+167.7%$17.4M+132.3%$14.8M+155.5%$11.7M+288.0%
Operating Income-$63.2Mn/m-$86.4Mn/m-$66.4Mn/m-$48.7Mn/m-$51.1Mn/m-$48.7Mn/m-$42.2Mn/m-$38.0Mn/m
EBITDA-$62.1Mn/m-$85.6Mn/m-$65.5Mn/mN/A-$50.7Mn/m-$48.6Mn/m-$42.2Mn/m-$38.0M
Net Income-$56.9Mn/m-$79.1Mn/m-$60.2Mn/m-$41.3Mn/m-$43.8Mn/m-$41.4Mn/m-$34.5Mn/m-$31.8Mn/m
EPS (Basic)-$0.64n/m-$0.90n/m-$0.71n/m-$0.51n/m-$0.57n/m-$0.54n/m-$0.45-$0.48
EPS (Diluted)-$0.64n/m-$0.90n/m-$0.71n/m-$0.51n/m-$0.57n/m-$0.54n/m-$0.45-$0.48
Diluted Shares (Avg)89M+15.8%88M+15.7%85M+10.9%N/A77M+14.3%76M+14.4%76MN/A

Not reported in any period shown, so not listed: Interest Expense, Income Tax.

CGON Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CGON quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$1.0B+43.4%$1.1B+54.8%$1.1B+55.9%$791.6M+4.9%$729.9M+32.1%$701.4M+24.3%$728.2M+25.7%$754.8M+278.7%
Current Assets$1.0B+44.8%$1.0B+56.0%$1.1B+57.2%$759.5M+0.7%$695.8M+26.0%$673.0M+19.4%$701.2M+21.2%$754.2M+288.5%
Cash & Equivalents$28.2M-37.4%$19.6M+34.3%$33.7M-18.7%$32.5M-87.4%$45.1M+4.0%$14.6M-41.9%$41.5M-46.5%$257.1M+3009.9%
Short-Term Investments$956.2M+50.6%$1.0B+56.0%$1.0B+61.1%$709.7M+46.3%$635.1M+27.7%$646.4M+22.5%$647.0M+32.3%$484.9M+170.3%
Inventory$1.2M-22.4%$1.0M$1.5M$1.6Mn/m$1.5MN/AN/A$0
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$10.3M-19.6%$10.3M0.0%$10.3M$10.3Mn/m$12.8M$10.3MN/A$0
Total Liabilities$55.7M+31.8%$56.5M+81.9%$43.5M+85.6%$39.0M+82.0%$42.3M+169.2%$31.1M+159.7%$23.4M+130.4%$21.4M-93.4%
Current Liabilities$46.4M+52.1%$47.2M+55.5%$35.2M+55.5%$30.8M+44.3%$30.5M+95.3%$30.4M+156.3%$22.6M+126.8%$21.4M+49.9%
Non-Current Liabilities$9.3M-21.0%$9.3M+1216.9%$8.3M+958.5%$8.2M+15580.8%$11.7M+16438.0%$706K+498.3%$781K+324.5%$52K-100.0%
Long-Term Debt$3.0M0.0%$3.0M$3.0M$3.0Mn/m$3.0MN/AN/A$0
Total Equity$991.0M+44.1%$1.0B+53.5%$1.1B+54.9%$752.6M+2.6%$687.6M+28.1%$670.4M+21.4%$704.8M+23.9%$733.4Mn/m
Retained Earnings-$575.1Mn/m-$518.2Mn/m-$439.2Mn/m-$379.0Mn/m-$337.7Mn/m-$293.9Mn/m-$252.4Mn/m-$218.0Mn/m

Not reported in any period shown, so not listed: Accounts Receivable.

CGON Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CGON quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$47.7Mn/m-$46.4Mn/m-$56.9Mn/m-$36.2Mn/m-$38.9Mn/m-$28.0Mn/m-$29.3Mn/m-$20.7Mn/m
Depreciation & Amortization$1.2M+177.6%$850K+444.9%$841K+3404.2%$849Kn/m$416K+1881.0%$156K+2128.6%$24K+500.0%$0-100.0%
Stock-Based Compensation$8.5M+15.3%$14.3M+104.6%$6.5M+25.7%N/A$7.3M+176.7%$7.0M+212.0%$5.2M+239.6%N/A
Capital Expenditures$1.1M+1049.5%$468K+3242.9%$304K+1800.0%$7K-96.7%$97K$14K0.0%$16K+33.3%$209K
Free Cash Flow-$48.8Mn/m-$46.9Mn/m-$57.2Mn/m-$36.2Mn/m-$39.0M-$28.0Mn/m-$29.3Mn/m-$20.9M
Investing Cash Flow$46.0M+206.0%$30.4M+2062.6%-$334.8Mn/m-$75.5M-792.4%$15.0M-53.0%$1.4Mn/m-$186.8Mn/m$10.9M-29.8%
Financing Cash Flow$10.3M-81.1%$1.9Mn/m$393.0M+87232.9%$99.1M-55.7%$54.4M+2409.0%-$296K-840.0%$450K-99.9%$223.4Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CGON Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CGON quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin-66.4%-71.7ppN/AN/AN/A5.3%N/AN/AN/A
Operating Margin-3943.2%-7467.7%-6130.1%-2097.3%-3069.0%N/A-81161.5%-8344.1%
Net Margin-3546.8%-6832.8%-5558.8%-1779.0%-2629.5%N/A-66253.8%-6973.2%
Return on Equity-5.7%+0.6pp-7.7%-1.5pp-5.5%-0.6pp-5.5%-1.2pp-6.4%-2.6pp-6.2%-2.8pp-4.9%-1.9pp-4.3%
Return on Assets-5.4%+0.6pp-7.3%-1.4pp-5.3%-0.6pp-5.2%-1.0pp-6.0%-2.3pp-5.9%-2.6pp-4.7%-1.8pp-4.2%+4.1pp
Current Ratio21.70-1.1x22.22+0.1x31.30+0.3x24.63-10.7x22.79-12.5x22.15-25.4x30.97-27.0x35.30+21.7x
Debt-to-Equity0.000.0x0.000.000.000.0x0.00N/AN/A0.00
Liabilities-to-Equity0.060.0x0.050.0x0.040.0x0.050.0x0.060.0x0.050.0x0.030.0x0.03
Asset Turnover0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x
FCF Margin-3043.8%-4052.0%-5286.0%-1560.0%-2340.4%N/A-56332.7%-4577.0%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
CG Oncology, Inc. CGON FY2025 $4.0M -$161.0M N/A $7.3B 61/100
ImmunityBio, Inc. IBRX FY2025 $113.3M -$351.4M N/A $7.0B 51/100
Oruka Therapeutics, Inc. ORKA FY2025 N/A -$105.4M N/A $6.6B —
Arrowhead Research Corporation ARWR FY2026 $450.8M -$724.2M N/A $6.2B 73/100
Belite Bio, Inc BLTE FY2025 N/A -$77.6M N/A $6.1B —
Abivax SA ABVX FY2025 $5.4M -$394.4M N/A $7.1B 54/100

Frequently Asked Questions

CG Oncology, Inc. (CGON) reported $4.0M in total revenue for fiscal year 2025. This represents a 254.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

CG Oncology, Inc. (CGON) revenue grew by 254.7% year-over-year, from $1.1M to $4.0M in fiscal year 2025.

No, CG Oncology, Inc. (CGON) reported a net loss of $237.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $161.0M.

CG Oncology, Inc. (CGON) reported diluted earnings per share of -$2.08 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CG Oncology, Inc. (CGON) had EBITDA of -$189.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, CG Oncology, Inc. (CGON) had $32.5M in cash and equivalents against $3.0M in long-term debt.

CG Oncology, Inc. (CGON) has a return on equity of -21.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

CG Oncology, Inc. (CGON) recorded an outflow of $132.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

CG Oncology, Inc. (CGON) recorded an outflow of $132.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

CG Oncology, Inc. (CGON) had $791.6M in total assets as of fiscal year 2025, including both current and long-term assets.

CG Oncology, Inc. (CGON) invested $134K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

CG Oncology, Inc. (CGON) invested $116.6M in research and development during fiscal year 2025.

CG Oncology, Inc. (CGON) had 84M shares outstanding as of fiscal year 2025.

CG Oncology, Inc. (CGON) had a current ratio of 24.63 as of fiscal year 2025, which is generally considered healthy.

CG Oncology, Inc. (CGON) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

CG Oncology, Inc. (CGON) had a liabilities-to-equity ratio of 0.05 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

CG Oncology, Inc. (CGON) had a return on assets of -20.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

CG Oncology, Inc. (CGON) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $7.3B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

CG Oncology, Inc. (CGON) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $6.2M revenue, trailing 12 months to September 30, 2026). The market capitalization is $7.3B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, CG Oncology, Inc. (CGON) held $742.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $132.3M over that year. Dividing the one by the other, the reported balance equals about 67 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

CG Oncology, Inc. (CGON) has an Altman Z-Score of 112.21, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

CG Oncology, Inc. (CGON) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

CG Oncology, Inc. (CGON) reported a net loss of $161.0M while operations used $132.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

CG Oncology, Inc. (CGON) scores 61 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top